Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986406 Monotherapy and Combination in Advanced Tumors
NCT05298592Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2022
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of BMS-986406 in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic ductal adenocarcinoma (PDAC) and 9 more (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events up to 100 days, Number of participants with serious adverse events up to 100 days and 3 more. Started Mar 2022; status: completed.
02
Drugs
BMS-986406
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)pancreatic ductal adenocarcinoma (PDAC)gastric cancer (GC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05298592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298592.